New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:44 EDTPCLN, GILDStocks with call strike movement; PCLN GILD
Priceline (PCLN) July 1490 call option implied volatility increased 6% to 35, Gilead (GILD) August 82.5 call option implied volatility increased 5% to 82.5 according to IVolatility.
News For PCLN;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 29, 2015
09:37 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL FB KO NFLX PFMT GILD YHOO TSLA MCD
08:44 EDTGILDUnitedHealth selects Gilead's Harvoni for hepatitis C coverage, Reuters says
Subscribe for More Information
07:04 EDTPCLNPriceline February volatility elevated into Q4 and outlook
Subscribe for More Information
January 28, 2015
09:35 EDTGILDActive equity options trading
Subscribe for More Information
January 27, 2015
16:00 EDTGILDOptions Update; January 27, 2015
iPath S&P 500 VIX Short-Term Futures up 1.40 to 32.01. Option volume leaders: AAPL TSLA TWTR AMZN FB MSFT X RIG YHOO C GILD according to Track Data.
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL MSFT TWTR TSLA GILD NFLX C AA HPQ X
08:53 EDTGILDGilead February weekly volatility elevated into Q4 and outlook
Subscribe for More Information
January 26, 2015
16:01 EDTGILDOptions Update; January 26, 2015
iPath S&P 500 VIX Short-Term Futures down 1.47 to 30.63. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX X MSFT BP GILD according to Track Data.
13:01 EDTGILDGilead, EnvisionRx sign exclusive agreement for Sovaldi, Harvoni availability
Subscribe for More Information
12:08 EDTPCLNPriceline price target lowered to $1,235 from $1,360 at Atlantic Equities
Subscribe for More Information
11:00 EDTGILDMylan expands Hepatitis C licensing agreement with Gilead
Mylan (MYL) announced that its subsidiary Mylan Laboratories Limited is expanding its hepatitis C licensing agreement with Gilead Sciences (GILD) to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816, once approved, in 91 developing countries. The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C. If approved by regulatory authorities, the sofosbuvir/GS-5816 regimen would become the first all-oral single tablet regimen for all hepatitis C genotypes. A pan-genotypic therapeutic option is particularly important for developing countries, where genotype testing is often unreliable or not readily available. This agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries. Mylan also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.
09:49 EDTGILDActive equity options trading
Subscribe for More Information
05:11 EDTGILDGilead expands hepatitis C generic licensing agreements
Subscribe for More Information
January 23, 2015
09:35 EDTGILDGilead mentioned cautiously at Cleveland Research
Subscribe for More Information
07:21 EDTPCLNDeutsche cautious on travel stocks into Q4 results
Subscribe for More Information
January 20, 2015
16:00 EDTGILDOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
14:09 EDTPCLNOrbitz jumps after Bloomberg says company may be exploring sale
Shares of online travel agency Orbitz Worldwide (OWW) are jumping after Bloomberg reported that the company is exploring the possibility of selling itself. In a note to investors on January 7, research firm FBR Capital wrote that the company could be acquired for over $10 per share, WHAT'S NEW: Orbitz is exploring a potential sale and private equity firms have expressed interest in acquiring the online travel agency, Bloomberg reported today. ANALYST VIEW: On January 7, research firm FBR Capital estimated that Orbitz could be acquired for $10.27 per share. The firm noted that a trade publication, Tnooz.com, had reported that Orbitz could be considering selling itself. Expedia (EXPE) and Priceline (PCLN) could each pay a premium of 30%-plus for Orbitz and still see their profits rise from the acquisition, FBR added. It kept a $9 price target and Outperform rating on Orbitz. PRICE ACTION: In mid-afternoon trading, Orbitz climbed 69c, or 7.5%, to $9.85.
13:51 EDTPCLNOrbitz draws private equity interest as sale explored, Bloomberg says
Orbitz Worldwide (OWW) is working with an adviser to contact potential buyers and has drawn interest from private-equity funds and "other Internet companies," according to Bloomberg, citing people with knowledge of the matter. Shares of Orbitz are up over 10% after the report, while several other names in the online travel space, such as Priceline (PCLN), Expedia (EXPE), and TripAdvisor (TRIP) are also moving. Reference Link
13:43 EDTPCLNExpedia, TripAdvisor tick higher after report on Orbitz sale exploration
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use